Aerovate Therapeutics Stock Today
| AVTE Stock | USD 2.05 0.06 3.02% |
Performance9 of 100
| Odds Of DistressLess than 17
|
Aerovate Therapeutics is trading at 2.05 as of the 7th of October 2024, a 3.02 percent increase since the beginning of the trading day. The stock's lowest day price was 1.99. Aerovate Therapeutics has less than a 17 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Aerovate Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of September 2024 and ending today, the 7th of October 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of June 2021 | Category Healthcare | Classification Health Care |
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. The company has 28.87 M outstanding shares of which 1.07 M shares are presently shorted by private and institutional investors with about 5.6 trading days to cover. More on Aerovate Therapeutics
Moving together with Aerovate Stock
Moving against Aerovate Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Aerovate Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAerovate Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aerovate Therapeutics' financial leverage. It provides some insight into what part of Aerovate Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Aerovate Therapeutics (AVTE) is traded on NASDAQ Exchange in USA. It is located in 930 Winter Street, Waltham, MA, United States, 02451 and employs 51 people. Aerovate Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 59.18 M. Aerovate Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 28.87 M outstanding shares of which 1.07 M shares are presently shorted by private and institutional investors with about 5.6 trading days to cover.
Aerovate Therapeutics currently holds about 151.99 M in cash with (56.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Aerovate Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Aerovate Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Aerovate Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Aerovate Therapeutics. Please pay attention to any change in the institutional holdings of Aerovate Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Aerovate Ownership Details
Aerovate Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ikarian Capital, Llc | 2024-06-30 | 368 K | |
| State Street Corp | 2024-06-30 | 341.2 K | |
| Geode Capital Management, Llc | 2024-06-30 | 317.2 K | |
| Two Sigma Investments Llc | 2024-06-30 | 278.8 K | |
| Verition Fund Managegment, Llc | 2024-06-30 | 249 K | |
| Adar1 Capital Management Llc | 2024-06-30 | 246.9 K | |
| Affinity Asset Advisors, Llc | 2024-06-30 | 200 K | |
| Sg Americas Securities, Llc | 2024-06-30 | 179.5 K | |
| Gsa Capital Partners Llp | 2024-06-30 | 126.6 K | |
| Ra Capital Management, Llc | 2024-06-30 | 9.2 M | |
| Sofinnova Ventures | 2024-06-30 | 3.8 M |
Aerovate Therapeutics Historical Income Statement
Aerovate Stock Against Markets
Aerovate Therapeutics Corporate Management
| Timothy Pigot | VP Commercial | Profile | |
| Benjamin Dake | President, Founder | Profile | |
| Timothy MBA | CEO Director | Profile | |
| Marinus Verwijs | Chief Officer | Profile | |
| Stephen Yu | Senior Quality | Profile | |
| BSc MD | Senior Development | Profile | |
| Hunter MD | Chief Officer | Profile |
Already Invested in Aerovate Therapeutics?
The danger of trading Aerovate Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aerovate Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aerovate Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aerovate Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Information and Resources on Investing in Aerovate Stock
When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.13) | Return On Assets (0.44) | Return On Equity (0.74) |
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.